

## Special Issue

# Axonal Pathology: From Cellular Mechanism to Therapy Targets

### Message from the Guest Editor

Loss of neurons represents the pathological event in neurodegenerative diseases. In the nervous system, axons convey the communication between neurons. The great sizes of axons make them vulnerable to various insults. Thus far, the majority of studies for potential mechanisms and therapeutic targets for neurodegenerative disorders have focused on events that occur in the cell bodies of neurons. However, white matter defects have been identified as an early neuropathological event, leading to axonal degeneration and eventual death of neurons in many neurodegenerative diseases. Therefore, we invite authors to submit original research and review articles that focus on the molecular mechanisms and therapeutic potential of axonal pathology. Potential topics include but are not limited to:

- Dystrophic neurite/axonal degeneration
- Cytoskeleton integrity
- Microtubule-based transport
- Ubiquitin–proteasome system
- Autophagy–lysosome system
- Growth factor signaling
- Mitochondria

### Guest Editor

Dr. Lu-Shiun Her

Department of Life Sciences, National Cheng Kung University, Tainan 70101, Taiwan

### Deadline for manuscript submissions

closed (15 June 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/122477](https://mdpi.com/si/122477)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).